Refine by
Microrna Articles & Analysis: Older
21 news found
Oligonucleotide Manufacturing BOC Sciences is a leading manufacturer of high-quality oligonucleotide products, including ASOs, siRNAs, aptamers, cap analogs, CpG ODNs, and microRNAs. Its oligonucleotides are widely used in research, diagnostics, and therapeutics, and are available in various sizes, purities, and modifications to suit different applications. ...
A groundbreaking study has developed a first-in-class, carbohydrate-coupled inhibitor of microRNA-21 (RCS-21), which shows significant potential as a therapeutic agent. ...
(“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant molecular diagnostic tests and pathology services for improved patient diagnosis and management, today announced new clinical validation data for their thyroid cancer test platform which is comprised of a mutation panel (ThyGeNEXT®) and a ...
These new data demonstrated that the addition of microRNA pairwise expression profiling (ThyraMIR®v2) provided clinically and statistically superior risk stratification of indeterminate thyroid nodules beyond that of the algorithmic classification analysis provided by the original ThyraMIR® assay. ...
Proprietary microRNA signature (miRisk) may support immunotherapy treatment decisions as a blood-based complementary diagnostic Results published in Journal of Thoracic Oncology Clinical and Research Reports Hummingbird Diagnostics GmbH, a leader in reading blood-based microRNAs for early disease detection and characterization, today announced a publication ...
Results describe development of analysis to uncover association of several microRNAs with overall survival following initiation of immunotherapy. ...
Johann Bauersachs, MD; Perry Elliott, MD; Gerasimos Filippatos, MD, PhD; and Barry Ticho, MD, PhD, will provide Cardior with important scientific, medical and development guidance as the company advances its lead program CDR132L, an oligonucleotide-based ncRNA inhibitor targeting microRNA-132, towards a Phase 2 clinical trial in patients with heart failure. ...
The SMRT-based transcriptomics platform provides a simple and accurate method for various applications, such as gene annotation, identification of transcript isoforms and fusion transcripts, long non-coding RNA (lncRNA) discovery, microRNA (miRNA) discovery, and prediction of potential mRNA target molecules. ...
The data confirm that the inhibition of the naturally occurring miR-132 microRNA via an antisense microRNA can prevent pathological cardiac remodeling in hypertrophic heart disease. ...
CDR132L blocks the naturally occurring microRNA miR-132 which, if overexpressed, is a key driver of heart ...
The compound is an antisense oligonucleotide inhibiting the non-coding microRNA-132 (miR132) that directly regulates adverse cardiac remodeling. ...
Session: Novel Biomarkers in Alzheimer's Disease Title: Circulating Brain-Enriched microRNAs as Peripheral Biomarkers of Neurodegeneration Date/Time: Tuesday, October 6, 2020, 2:35 pm EDT About International Conference on Alzheimer's Drug Discovery The purpose for this annual ADDF conference is to accelerate the development of innovative treatments and biomarkers for Alzheimer's ...
ByDiamiR
The patent covers the use of methods developed by DiamiR based on targeted quantitative analysis of microRNAs enriched in the brain and detectable in blood plasma as biomarkers of brain aging. ...
ByDiamiR
Bruno Steinkraus, Ph.D. and colleagues at Hummingbird Diagnostics in Germany (up to $708,382 award) are developing a blood test that detects bloodborne microRNAs, molecules that help maintain the integrity of neurons in the brain and are surrogate markers of the immune system. Levels of microRNAs in the blood appear to be a reliable biomarker showing progression ...
"In this study we will specifically focus on evaluating associations between changes in the plasma levels of microRNAs enriched in the specific brain regions affected by the disease and other known AD markers. ...
ByDiamiR
"Our novel diagnostic approach focuses on detecting changes in the plasma levels of microRNAs enriched in the specific brain regions affected by the disease. ...
ByDiamiR
Hanover, Germany, November 1, 2018 - Cardior Pharmaceuticals GmbH, a company focused on the development of noncoding RNA (ncRNA) therapeutics for patients with myocardial infarction and heart failure, today announced it has acquired a portfolio of four microRNA (miRNA) patents from Bayerische Patentallianz GmbH (BayPAT). miRNAs are short pieces of ncRNA native to all human cells ...
SomaGenics’ technology allows discrimination of miRNA isomiRs/isoforms with single-nucleotide specificity and single-cell sensitivity. “Although microRNAs are considered viable biomarkers, they have been difficult to identify and validate due to the poor accuracy of detection by commonly used RT-qPCR and NGS methods which often leads to inconsistent and ...
Research over the past year has demonstrated changes in specific plasma microRNAs (micro ribonucleic acids) in TBI patients over a period of several months. ...
SurePrint gene expression microarrays are part of the SurePrint product family, which includes microRNA and comparative genomic hybridization microarrays. Agilent's genomic workflow includes the 2100 Bioanalyzer and 2200 Tapestation for quality control, SureScan scanner for data acquisition, GeneSpring software for data analysis, and the AriaMX system for real-time polymerase ...